>> I see you noticed the marked decline in HGSI p/s over the last few weeks. Any other reason beside its investments in mortgage backed securities? <<
Yeah. There has been some concern about their best shot-on-goal, Albuferon. The drop-out rate in the P2b Albuferon trial was pretty high, there is a concern that 48 weeks treatment for genotype 1 won't be needed if any of the new HCV drugs make it to market, and there is competition coming up from behind in the once-every-two-weeks IF-alpha race.
But in my judgement, a lot of the recent drop in HGSI's stock price is probably due to those mortgage-backed securities. There are other companies with a lot of mortgage-backed securities which have suffered similarly.
micro
Market Data 
Markets 
AI
